FRANCESCO BLASI, M.D.

Professor of Respiratory Medicine,

Department Pathophysiology and Transplantation, University of Milan-Italy

Born in Milan, 18.11.1959

1984 MD degree	University of Milan Italy		
Specialty Certification			
1987	Diplomate-Cardiology : University of Milan-Italy		
1991	Ph.D. Respiratory Diseases: University of Milan-Italy		
1997	Diplomate-Respiratory Dis : University of Milan-Italy		
University appointments			
JUNE 1991-MAY 1992	Ricercatore universitario (Assistant Professor)		
	Institute of Internal Medicine, University of Milan-Italy		
JUNE 1992-2000	Ricercatore universitario (Assistant Professor)		
	Institute of Respiratory Diseases, University of Milan-Italy		
MARCH 2001	Professore Associato (Associate Professor)		
	Institute of Respiratory Diseases, University of Milan-Italy		
DECEMBER 2002	ofessore Ordinario (full Professor) Respiratory Medicine,		
	Institute of Respiratory Diseases, University of Milan-Italy		
JANUARY 2009	Professore Ordinario (full Professor) Respiratory Medicine,		
	Cardiothoracic Department, University of Milan-Italy		
JANUARY 2012	Professore Ordinario (full Professor) Respiratory Medicine,		
	Department Pathophysiology and Transplantation, University of		
	Milan-Italy		

-Vice Chairman Department Pathophysiology and Transplantation, University of Milan, Italy

-Head of Cardio-thoracic Unit, Dept of Transplantation Units, Fondazione Ospedale Maggiore Policlinico Ca' Granda, Milan Italy

-Director of the School of Specialty in Respiratory Diseases University of Milan Italy 2005-2009 and 2013-16 - President European Respiratory Society 2012-13

-Head of Respiratory Infection Assembly, European Respiratory Society (member of the Executive Committee) 2005-2008

-Member of the ERS task force on Guidelines for LRTIs management 2003-2010

-Member of the Executive Committee of the Italian Respiratory Society (SIMeR) 2000-2010

-President elect of the Italian Respiratory Society (SIMeR) 2014

Teaching Certificate Award for educational presentations European School of Respiratory Medicine (European Respiratory Society) 1996 - 1997 - 1999 - 2000 - 2001 - 2002 - 2003 - 2004 - 2005 - 2006-2007-2008-2009-2010-2011

Main Publications in the last 4 years

-Piacentini GL, et al. Atypical bacteria in adenoids and tonsils of children requiring adenotonsillectomy. Acta Otolaryngol. 2010; 130: 620-625

-Blasi F, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010; 23: 200–207.

-Aliberti S, et al. Duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia. Eur Respir J 2010; 36: 128–134

-Mirsaeidi M, et al. Thrombocytopenia and Thrombocytosis at Time of Hospitalization Predict Mortality in Patients with Community-Acquired Pneumonia. Chest. 2010;137:416-20

-Miravitlles M, et al. TB or not TB: update from the ERS Respiratory Infection Assembly 10. Eur Respir J 2010; 36: 665–670

-Butler CC, et al. Treatment of acute cough/lower respiratory tract infection by antibiotic class and associated outcomes: a 13 European country observational study in primary care. J Antimicrob Chemother 2010; 65: 2472–247

-Blasi F, et al. Biomarkers in lower respiratory tract infections. Pulm Pharmacol Ther. 2010;23: 501-7

-Arnold FW, et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med. 2010 Nov; 104(11):1736-43.

-Blasi F, et al. Role of the oral beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations. J Chemother 2010;22 S1: 3-28

-Migliori GB, et al. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC). Eur Respir J. 2011 Sep;38(3):493-5

-Aliberti S, et al Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia.Respir Med. 2011 Nov;105(11):1732-8.

-Blasi F, et al. Healthcare workers and influenza vaccination: an ERS-ESCMID Web-based survey.Clin Microbiol Infect. 2011 Aug;17(8):1223-5

-Miravitlles M, et al. The best on infections: update from the 2010 ERS Congress. Eur Respir J. 2011 Aug;38(2):450-5. -Butler CC, et al. Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection. Eur Respir J. 2011 Jul;38(1):119-25

-Riquelme R, et al. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. Int J Tuberc Lung Dis. 2011 Apr;15(4):542-6.

-Aliberti S, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011 Aug;140(2):482-8

-Wood J, et al Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J. 2011 Jul;38(1):112-8.

-Woodhead M, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011 Nov;17 Suppl 6:E1-59.

-Woodhead M, et al. Guidelines for the management of adult lower respiratory tract infections--summary. Clin Microbiol Infect. 2011 Nov;17 Suppl 6:1-24.

-Aliberti S, et al. Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia. Clin Infect Dis. 2012;54:470-478

-Blasi F, et al. Antibiotics as immunomodulant agents in COPD. Curr Opin Pharmacol 2012;12:293-9

-Di Marco F, et al Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: A pilot study. Pulm Pharmacol Ther. 2012; 25:119-123

-Zumla A, et al.Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. Eur Respir J. 2012;39:802-4

-Migliori GB, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39:807-19.

-Aliberti S, et al. Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores. Clin Infect Dis. 2012;54(10):1519-20

-Migliori G, et al. Protecting the TB drug pipeline. Stating the case for the rational use of Fluoroquinolones. Eur Respir J 2012 40:814-822

-Santus P, et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res. 2012; 66(4):343-8

-Aliberti S, et al. Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia. Semin Respir Crit Care Med. 2012 Jun;33(3):284-91

-Falcone M, et al. Pneumonia in frail older patients: an up to date. Intern Emerg Med. 2012;7:415-424

-Santus P, Pet al. Doctor-patient relationship: A resource to improve respiratory diseases management. Eur J Intern Med. 2012 Jul;23(5):442-6.

-Blasi F, et al. The role of biomarkers in low respiratory tract infections. Eur J Intern Med. 2012 Jul;23(5):429-35 -Aliberti S, et al. The management of patients with community-acquired pneumonia beyond antibiotic therapy. Eur J Intern Med. 2012 Jul;23(5):389-90

-Finch RG, et al. GRACE and the development of an education and training curriculum. Clin Microbiol Infect. 2012 Sep;18(9):E308-E313

-Blasi F, et al. Compliance with anti-H1N1 vaccine among healthcare workers and general population.Clin Microbiol Infect. 2012;18 (Suppl. 5) 37–41

-Blasi F, et al. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18 (Suppl. 5): 7–14

-Santus P, et al. How air pollution influences clinical management of respiratory diseases. A case-crossover study in Milan. Respir Res. 2012 Oct 18;13(1):95.

-Vugt SV, et al. Airway Obstruction and Bronchodilator Responsiveness in Adults With Acute Cough. Ann Fam Med. 2012 Nov;10(6):523-529

-van Vugt S, et al. Incidental Chest Radiographic Findings in Adult Patients With Acute Cough. Ann Fam Med. 2012 Nov;10(6):510-515

-Little P, et al. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis. 2013 Feb;13(2):123-129.

-Blasi F, et al. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Therapeutics and Clinical Risk Management 2013:9 55–64

-Bordon J, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia.

Int J Infect Dis. 2013; 17(2):e76-83

-Blasi F, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J. 2013 Mar; 41(3):491-4.

-Blasi F, et al. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res. 2013 Apr 15;14(1):44.

-van der Werf MJ, et al. Lessons learnt in Europe on tuberculosis surveillance, outbreaks and BCG vaccination in 2011. Eur Respir J. 2013 Apr;41(4):767-71.

-Aliberti S, et al. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2013; 42(3):742-9.

-Bordon J, et al. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. Int J Infect Dis. 2013 May; 17(5):e293-8

-Blasi F, et al. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with Acute Exacerbations of Chronic Bronchitis. Pulm Pharmacol Ther. 2013; 26(5):609-16

-Cillóniz C, et al Impact of Age and Comorbidity on Etiology and Outcome in Community-Acquired Pneumonia. Chest. 2013;144(3):999-100

-Garau J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19: E377–E385

-Esperatti M, et al. Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU. Crit Care Med. 2013;41(9):2151-2161

-Di Pasquale M, et al. Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. Intensive Care Med. 2013;39(10):1776-84

-Giunta V, et al .ICU-Acquired Pneumonia With or Without Etiologic Diagnosis: A Comparison of Outcomes.Crit Care Med. 2013;41(9):2133-43

-Blasi F, et al. Future directions for the ERS: presidential plans. Eur Respir J. 2013 ;42:875-80

-Blasi F, et al.Reaching the golden milestone. The 2013 ERS Dublin summit: preparing the road to Rome. Eur Respir J. 2013;42:881-4.

-Schraufnagel DE, et al. An official American Thoracic Society and European Respiratory Society policy statement: disparities in respiratory health. Eur Respir J. 2013 ;42:906-15.

-Schraufnagel DE, et al An official American Thoracic Society/European Respiratory Society policy statement: disparities in respiratory health. Am J Respir Crit Care Med. 2013 Oct 1;188(7):865-71.

-Blasi F, et al. Innovation in lung health research-a Copernican revolution? Lancet Respir Med. 2013 Sep;1(7):506-7 -Cavallazzi R, et al. Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. Eur Respir J. 2013 ; 43:178-84.

-Aliberti S, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax. 2013; 68: 997-999

-Diel R, et al.Old ideas to innovate TB control: preventive treatment to achieve elimination. Eur Respir J. 2013; 42:785-801

-Sterrantino C, et al Burden of Community-Acquired Pneumonia in Italian general practice. Eur Respir J. 2013;42:1739-42

-Di Pasquale M, et al. Assessment of Severity of ICU-Acquired Pneumonia and Association With Etiology. Crit Care Med. 2014 Feb;42(2):303-12

-Blasi F, et al.Indicator condition-guided HIV testing in Europe: a step forward to HIV control. Eur Respir J. 2013 Sep; 42(3):572-5.

-Braido F, et al. Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respir Res. 2013 Sep 22;14(1):94

- D'Ambrosio L, et al. ERS/WHO TB consilium: reporting on initial 10 cases. Eur Respir J. 2014 Jan;43(1):286-9.

-Torres A, et al. Risk factors for community-acquired pneumonia

in adults in Europe: a literature review. Thorax 2013;68:1057–1065.

-D'Ambrosio L, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J. 2014

-Barnes PJ, Blasi F, Ward B, Reeves E, Rabe KF. Respiratory diseases in the world: one voice "united for lung health". Eur Respir J. 2014 Jan;43(1):3-5.

-Grossman RF, et al. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis. 2014; 18: 14-21

-Blasi F, et al. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. Resp Res 2014, 15 :6

-Stolz D, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD - The "BODE-A" index.Eur Respir J. 2014; 43(2):397-408

INDEXES (1.1.2014) :

Papers: 293	Cites/paper:17.98	h-index:35	AWCR: 550.63
Citations:5268	Cites/author: 1283.72	g-index: 69	AW-index: 23.47
Years: 27	Papers/author: 102.95	hc-index: 25	AWCRpA:134.02
Cites/year:195.11	Authors/paper: 3.76	hI-index: 7.56	e-index: 53.45
-		hI,norm: 19	hm-index:15.53

Research Support.

Completed Research Support

Ospedale Maggiore Milano Grant 260-01-2000 and Italian Multiple sclerosis patient association 01/2001-12/2002 Chlamydia pneumoniae infection in Italian multiple sclerosis patients

This study addressed the possible role of C.pneumoniae infection in the pathogenesis of multiple sclerosis Role: Co

investigator Ospedale Maggiore Milano GRANT 260-02-2001 and Abbott unrestricted grant 05/2002-07/2003 Atypicals involvement in upper respiratory tract infection in children This was the first study on a large sample of children showing the importance of the role of these pathogens in upper RTIs Role: Co-investigator Ospedale Maggiore Milano GRANT 260-01-2002 University of Milan Grant FIRST 2002 02/2003-11/2003 Proteomic analysis of exhaled breath condensate from healthy smokers The study showed the presence of Keratin in exhaled breath condensate of smokers, a possible marker of metaplasia Role: PI Istituto Superiore di Sanità Roma and Ospedale Maggiore Milano GRANT 260-01-2003 08/2004-12/2004 New assays for the diagnosis of SARS Two new serologic assays were published Role: Coinvestigator Pfizer unrestricted grant and Ospedale Maggiore 260-02-2003 01/2003-02/2004 Role of atypical pathogens in recurrent respiratory infections in children Randomized prospective study on the role of azithromycin in preventing recurrences of RTIs Role : Co-investigator Pfizer unrestricted grant and Ospedale Maggiore 260-01-2004 Azithromycin in the prophylaxis of respiratory recurrences in patients with tracheostoma Role: PI Ospedale Maggiore Milano grant 260-02-2004 Proteomic analysis of exhaled breath condensate in Cystic fibrosis children Role: PI University of Milan Grant FIRST 2004 and Ospedale Maggiore Milano grant 260-01-2005 Role of inflammatory cytokines analysis in exhaled breath condensate in the evaluation of early diagnosis of rejection in pulmonary transplantation Role : PI University of Milan Grant FIRST 2004 Role of infections in pulmonary hypertension Role: Co-Investigator PRIN 2005 Bronchiectasie nel paziente con BPCO: prevalenza e colonizzazione batterica. prot. 2005067041 Role: PI SIXTH FRAMEWORK PROGRAMME PRIORITY [LSH-2004-2.1.2] NETWORK OF EXCELLENCE Project acronym: GRACE Project full title: Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe Contract no.: PL518226 Role: Co-chair WP12 Educational workpackage and Co-investigator WP 8,9,10

SIXTH FRAMEWORK PROGRAMME PRIORITY

Project acronym: CHAMP Project full title: Changing behaviour of Health care professionals And the general public towards a More Prudent use of anti-microbial agents Role: Partner Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico 2010-2012 Project 260-325-140 Management of Lung Transplantation: from animal model to human lung regeneration Role: Coordinator

Prof Blasi serve(d)s as PI or national coordinator of several trials funded by pharmaceutical industries mainly in COPD, Asthma and pneumonia.

I hereby declare that I have experience in performing clinical trials according to GCP.

Milan 05.03.2014

my Shi

Francesco Blasi, MD -

Dipartimento Fisiopatologia e dei Trapianti, University of Milan, Pad. Sacco, Fondazione IRCCS Ospedale Maggiore di Milano. tel. +39 02 50320627, fax +39 02 50320625, E-mail: <u>francesco.blasi@unimi.it</u>